In a nutshell This article looks at the effect that autologous stem cell transplantation has on the fertility of women with Hodgkin or non-Hodgkin lymphoma. The study concluded that women had a surprisingly high rate of good fertility outcomes after autologous stem cell transplantation. Some background Autologous stem cell transplantation...
Read More
In a nutshell This study presented guidelines for the treatment and follow-up of mantle cell lymphoma presented by the European Society for Medical Oncology. Some background Mantle cell lymphoma (MCL) is a rare but usually aggressive type of non-Hodgkin lymphoma. Patients often experience multiple relapses after first- and second-line...
Read More
In a nutshell In this review, the authors look at the most common adverse events related to ibrutinib and idelalisib, B-cell inhibitors. The study concluded that both ibrutinib and idelalisib are effective at treating B-cell cancers, and the side effects are within a normal range compared to other similar treatments. Some...
Read MoreIn a nutshell The authors looked at the outcomes for patients with non-Hodgkin lymphoma who were treated with bendamustine (Treanda). The authors concluded that bendamustine has good long-term outcomes for patients with non-Hodgkin lymphoma, especially when combined with rituximab (Rituxan). Some background Bendamustine has long been a...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness a combination of ibrutinib (Imbruvica) and rituximab (Rituxan) with hyper-CVAD and MTX-AraC chemotherapy in treating mantle cell lymphoma (a cancer of B-cells). The primary outcome will be measured by overall response and side effects. This trial is taking place at the University...
Read More
In a nutshell This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression. The details Copanlisib is an inhibitor of...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of an ibrutinib (Imbruvica) and rituximab (Rituxan) combination in treating patients with relapsed or refractory mantle cell lymphoma (MCL) or newly diagnosed elderly patients. The primary objective will be measured by the response rate. This trial is being conducted...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of topical SGX301 (synthetic hypericin) in treating patch or plaque phase mycosis fungoides. The primary outcome will be measured by the treatment response. The details Mycosis fungoides cutaneous T-cell lymphoma (CTCL), is a cancer of T-cells involving the skin. During the...
Read More
In a nutshell This phase 1 clinical trial will test the safety of a JCAR014 engineered T cells and durvalumab (MEDI4736) combination in treating recurrent or refractory (unresponsive to treatment) non-Hodgkin’s lymphoma. The primary outcome will be measured by evaluating the movement of the engineered T cells throughout the body and side...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of ibrutinib (Imbruvica) during and after stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma. The primary outcome will be measured by the time to disease progression. The details Ibrutinib is a drug that stops the growth of...
Read More
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of yttrium-90 (Y-90)-ibritumomab tiuxetan (Zevalin) followed by fludarabine (Fludara), total body irradiation, and donor peripheral blood stem cell transplant (PBSCT) in patients with relapsed or refractory (did not respond to treatment) B-cell lymphoma. The primary...
Read More
